Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PL3N
|
|||
| Drug Name |
Gefapixant
|
|||
| Synonyms |
UNII-6K6L7E3F1L; 6K6L7E3F1L; MK-7264; 1015787-98-0; Gefapixant [USAN]; GTPL9540; SCHEMBL1493905; CHEMBL3716057; HLWURFKMDLAKOD-UHFFFAOYSA-N; ZINC116342482; J3.556.891C; 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide; 2-Methoxy-4-isopropyl-5-(2,4-diamino-5-pyrimidinyloxy)benzenesulfonamide; 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide; 5-((2,4-Diaminopyrimidin-5-yl)oxy)-2-methoxy-4-(propan-2-yl)benzenesulfonamid
Click to Show/Hide
|
|||
| Indication | Cough [ICD-11: MD12; ICD-10: R05; ICD-9: 786.2] | Phase 3 | [1] | |
| Overactive bladder [ICD-11: GC50.0; ICD-10: N32.8] | Phase 2 | [2] | ||
| Company |
Merck, Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H19N5O4S
|
|||
| Canonical SMILES |
CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
|
|||
| InChI |
1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
|
|||
| InChIKey |
HLWURFKMDLAKOD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1015787-98-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P2X purinoceptor 3 (P2RX3) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | ClinicalTrials.gov (NCT02477709) A Study to Assess the Tolerability of a Single Dose of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.